19 Nov 2025 | 5 Mins Read
Bal Pharma sees 0.45% Y-o-Y sales growth in September 2025
Flipitmoney
Bal Pharma's consolidated quarterly numbers for September 2025 are as follows: Net Sales Rs 74.02 crore (up 0.45%), Net Profit Rs 0.71 crore (down 31.78%), and EBITDA Rs 6.85 crore (down 8.54%). EPS decreased to Rs 0.45 in September 2025 from Rs 0.65 in September 2024, with shares closing at 79.06 on November 17, 2025, down -21.01% and -37.53% over the last 6 and 12 months respectively.